Statins as acute-stroke treatment

International Journal of Stroke

Volumn 1, Issue 4, 2006, Pages 224-225

  Elkind, Mitchell S V ^a,b,c  

^a Columbia University ^*  (United States)

^b Vagelos College of Physicians and Surgeons   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ATORVASTATIN; COMPACTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RHO FACTOR; ROSUVASTATIN; SIMVASTATIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN BLOOD FLOW; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVITY; HEART INFARCTION; HUMAN; INHIBITION KINETICS; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECURRENCE RISK; RISK REDUCTION; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ACYL COENZYME A; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; STROKE;

EID: 33749639810     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2006.00061.x     Document Type: Article

References (20)

1. Amarenco P, Labreuche J, Lavallee P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902-9.
2. Ballantyne CM: Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the heart protection study on standards of efficacy and safety. Am J Cardiol 2003; 92 (Suppl.): 3K-9K.
3. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med 2006; 355: 549-59.
4. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002; 360:7-22.
5. Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95:8880-5.
6. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA: Mevastatin, an HMG-coa reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001; 32:980-6.
7. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M: Rosuvastatin, a new HMG-coa reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002; 942:23-30.
8. Gertz K, Laufs U, Lindauer U et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34:551-7.
9. Kawashima S, Yamashita T, Miwa Y et al. HMG-coa reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003; 34:157-63.
10. Rikitake Y, Kim HH, Huang Z et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36:2251-7.
11. Sironi L, Cimino M, Guerrini U et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003; 23:322-7.
12. Chen J, Zhang ZG, Li Y et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53:743-51.
13. Zhang L, Zhang ZG, Ding GL et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 2005; 29:3486-94.
14. Jonsson N, Asplund K: Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 2001; 32:1112-5.
15. Marti-Fabregas J, Gomis M, Arboix A et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35:1117-21.
16. Greisenegger S, Mullner M, Tentschert S, Lang W, Lalouschek W: Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004; 221:5-10.
17. Elkind MSV, Flint AC, Sciacca RR, Sacco RL: Use of lipid lowering agents prior to onset of ischemic stroke is associated with decreased mortality: The Northern Manhattan stroke study. Neurology 2005; 65:253-8.
18. Montaner J, Chacon P, Krupinski J et al. Safety and efficacy of statins in the acute phase of ischemic stroke: The MISTICS trial. Stroke 2004; 35:293.
19. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M: HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005; 36:1298-300.
20. Bushnell CD, Griffin J, Newby LK et al. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke 2006; 37:1427-31.